

## Product datasheet for TL301707V

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## SHMT1 Human shRNA Lentiviral Particle (Locus ID 6470)

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** SHMT1 Human shRNA Lentiviral Particle (Locus ID 6470)

Locus ID: 6470

CSHMT; SHMT Synonyms:

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: SHMT1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

NM 001281786, NM 004169, NM 148918, NM 004169.1, NM 004169.2, NM 004169.3, RefSeq:

NM 004169.4, NM 148918.1, NM 148918.2, NM 001281786.1, BC007979, BC007979.2,

BC022874, BC022874.1, BC038598, BM792235

UniProt ID: P34896

This gene encodes the cytosolic form of serine hydroxymethyltransferase, a pyridoxal **Summary:** 

phosphate-containing enzyme that catalyzes the reversible conversion of serine and

tetrahydrofolate to glycine and 5,10-methylene tetrahydrofolate. This reaction provides onecarbon units for synthesis of methionine, thymidylate, and purines in the cytoplasm. This

gene is located within the Smith-Magenis syndrome region on chromosome 17. A

pseudogene of this gene is located on the short arm of chromosome 1. Alternative splicing

results in multiple transcript variants. [provided by RefSeq, Aug 2013]

These shRNA constructs were designed against multiple splice variants at this gene locus. To shRNA Design:

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>.

If you need a special design or shRNA sequence, please utilize our custom shRNA service.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).